Chongqing Huasen Pharmaceutical announced that five of its products have been newly included in the National Essential Medicines List 2026 Edition issued by the National Health Commission. The newly selected varieties include Duliang Soft Capsules, Ganju Bingmei Tablets, Terazosin, Cilostazol, and Acyclovir for Injection. The list will take effect from September 1, 2026. Among the specifications previously included in the 2018 Essential Medicines List, only Isoniazid Tablets have been removed this time, while all other specifications remain. The company stated that inclusion in the Essential Medicines List will help further expand the primary healthcare market, increase market share, and have a positive impact on long-term development, but the specific short-term impact on performance cannot yet be determined.
Chongqing Pharscin Pharmaceutical Co LtdFive products newly included in National Essential Medicines List, expected to expand primary healthcare market and increase market share.